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Macrophage and adipocyte 
interaction as a source 
of inflammation in kidney disease
Cristina Martos‑Rus1, Goni Katz‑Greenberg1, Zhao Lin2, Eurico Serrano1, 
Diana Whitaker‑Menezes2, Marina Domingo‑Vidal2, Megan Roche2, Kavitha Ramaswamy1, 
Douglas C. Hooper3, Bonita Falkner1 & Maria P. Martinez Cantarin1*
In obesity, adipose tissue derived inflammation is associated with unfavorable metabolic 
consequences. Uremic inflammation is prevalent and contributes to detrimental outcomes. However, 
the contribution of adipose tissue inflammation in uremia has not been characterized. We studied 
the contribution of adipose tissue to uremic inflammation in‑vitro, in‑vivo and in human samples. 
Exposure to uremic serum resulted in activation of inflammatory pathways including NFκB and 
HIF1, upregulation of inflammatory cytokines/chemokines and catabolism with lipolysis, and lactate 
production. Also, co‑culture of adipocytes with macrophages primed by uremic serum resulted in 
higher inflammatory cytokine expression than adipocytes exposed only to uremic serum. Adipose 
tissue of end stage renal disease subjects revealed increased macrophage infiltration compared to 
controls after BMI stratification. Similarly, mice with kidney disease recapitulated the inflammatory 
state observed in uremic patients and additionally demonstrated increased peripheral monocytes 
and inflammatory polarization of adipose tissue macrophages (ATMS). In contrast, adipose tissue in 
uremic IL‑6 knock out mice showed reduced ATMS density compared to uremic wild‑type controls. 
Differences in ATMS density highlight the necessary role of IL‑6 in macrophage infiltration in uremia. 
Uremia promotes changes in adipocytes and macrophages enhancing production of inflammatory 
cytokines. We demonstrate an interaction between uremic activated macrophages and adipose tissue 
that augments inflammation in uremia.
Patients with end stage renal disease (ESRD) have high circulating levels of inflammatory markers such as 
CRP, IL-6, TNFα, and IL-1α1,2. Clinical evidence of increased inflammation is associated with poor out-
comes in patients with ESRD on hemodialysis, peritoneal dialysis, and in chronic kidney disease (CKD) after 
 transplantation3–8. Inflammation plays a role in the development of multiple complications of kidney disease 
including protein energy  wasting9,  anorexia10, anemia, vascular  calcification11, and endocrine disorders including 
insulin resistance. Inflammation is also now considered a novel and independent risk factor for cardiovascular 
 disease12,13.
The process by which kidney disease causes inflammation is poorly understood and many potential mecha-
nisms have been described. We previously demonstrated greater macrophage infiltration in adipose tissue of 
uremic patients compared to normal kidney function  controls14. In obesity, adipose tissue macrophages (ATMS) 
are the most common white blood cells that infiltrate adipose tissue. The number of macrophages present in obese 
adipose tissue directly correlates with degree of adiposity and with adipocyte size in both human subjects and 
mice, with no differences present between subcutaneous and visceral adipose depots. Macrophages in adipose 
tissue are a significant source of circulating TNFα and IL-6. In humans with non-inflammatory conditions, 
adipose tissue contributes up to 35% of the total circulating IL-6  levels15. In inflammatory conditions such as 
obesity, the production of inflammatory cytokines by the adipose tissue can increase up to 50% of the circulat-
ing  pool16. Therefore, it is plausible that the contribution of adipose tissue inflammatory cytokines to the overall 
inflammatory states seen in uremia is significant. A close relationship between macrophages and adipocytes has 
been demonstrated in obesity. Hypertrophic/hyperplastic adipocytes produce chemokines that will promote 
macrophage infiltration in  obesity17. Once macrophages migrate to the obese adipose tissue, they acquire an 
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inflammatory  phenotype18. Inflammatory ATMS in obesity are the main source of adipose tissue inflammatory 
cytokines, which promote detrimental metabolic effects associated with  obesity19 including insulin resistance 
and adipocyte  dysfunction16. However, adipose tissue dysfunction in uremia and its potential contribution to 
inflammation has not been characterized. Furthermore, the role of adiposity in ESRD and its contribution to 
patient outcomes has been a long-standing debate. Traditionally, obese ESRD patients on dialysis were thought 
to have a survival  advantage20,21, but this view has been recently challenged. Stenvinkel et al. reported evidence 
that inflammation modifies the relationship of obesity with mortality in ESRD  patients22, supporting the concept 
that inflammation in ESRD patients is associated with excess morbidity independent of adiposity. With this 
background, we designed a series of experiments to investigate macrophage and adipose tissue inflammatory 
responses to uremia. Our experiments include in-vitro cell models with exposure to uremic serum, an in-vivo 
mouse model of uremia, and human tissue studies.
Results
Adipokine expression and glycolysis in 3T3‑L1 adipocytes is increased after uremia expo‑
sure. To determine the effects of uremia on adipose tissue function, we studied adipokine production in a 
3T3-L1 cell model. Cells exposed to uremic serum increased expression of IL-6, IL-1α, and adiponectin (Fig. 1A). 
Since uremic patients have increased circulating adiponectin  levels1, we studied adiponectin expression in cell 
membrane and cytosolic fractions to delineate the origin of the higher adiponectin levels observed in 3T3-L1 
cells exposed to uremia. As seen in Fig. 1B, both the membrane and cytosolic fractions of 3T3-L1 cells exposed 
to uremia demonstrated higher adiponectin protein reflecting increased adiponectin production as well as adi-
ponectin binding to the cell membrane. Since inflammation can promote glycolysis and patients with advanced 
kidney disease have higher circulating free fatty acids, we studied adipose tissue catabolism, specifically lipolysis 
levels. Figure 1C shows increased glycerol release in 3T3-L1 cells exposed to uremic serum compared to control 
serum, more prominently at 24  h and 40  h post-exposure. Figure  1D,E shows rates of oxygen consumption 
(OCR) in 3T3L1 cells exposed to uremic serum. In concordance with the increased lipolysis, cells exposed to 
uremia show increased basal respiration and proton leak rates. The increase in OCR in 3T3L1 cells exposed to 
Figure 1.  Adipokine expression and glycerol release in 3T3-L1 adipocytes is increased after uremic serum 
exposure. Differentiated 3T3-L1 cells were exposed to different concentrations of control and uremic serum. 
(A) IL-6, IL-1⍺, TNF⍺ and CCL2 mRNA expression levels assessed by RT-qPCR after cells were exposed 
to 10% uremic and 10% control serum. (B) Adiponectin content assessed by western blot in membrane and 
cytosolic compartment after 3T3-L1 cells were exposed to control and uremic serum (cropped membrane, full 
length blots are presented in Figure S4). (C) Free glycerol in media from 3T3L1 after treatment with control 
and uremic serum for 24 h. (D,E) OCR measurements in 3T3-L1 cells treated with control and uremic serum 
for 24 h. (E) Shows the representative time course data for OCR. (E) Shows the aggregated data. Data from 
OCR experiments represent the mean of four technical replicates from two representative experiments. (F) 
CPT-1α mRNA expression levels assessed by RT-qPCR after cells were exposed to 5–10% uremic and control 
serum. Unpaired t test, n = 4 for (A–D), experiments were done in triplicate, error bars represent SEM. *p < 0.05 
**p < 0.01 C, control. U, uremic. Full length blots are presented in Figure S4.
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uremia may be related to an increase in free fatty acid oxidation as expression of carnitine palmitoyltransferase I 
alpha (CPT-1α) is increased (Fig. 1F). The activity of CPT-1α is rate-limiting in fatty acid oxidation. These data 
demonstrate a significant change in adipose cell endocrine function and metabolism in uremia with increased 
production of inflammatory cytokines and lipolysis.
Monocyte/macrophage cytokine production is heightened after uremia exposure. Since ure-
mia alters adipose tissue cytokine production and increases ATMS  infiltration14, we studied the effects of uremia 
on macrophage function by investigating their cytokine production after exposure to uremic serum. Human 
THP-1 monocytes incubated with uremic serum significantly increased expression of IL-6, TNFα, CCL2 and, to 
a lesser extent, IL-10 without any changes in the expression of arginase 1 (ARG1) (Fig. 2A). Comparable results 
were obtained using the HL60 cell line and THP-1 macrophages treated with phorbol 12-myristate 13-acetate 
(PMA) to induce macrophage differentiation. Both cell lines exposed to uremia have also a significant increase 
in the expression of IL-6, TNFα, and CCL2 without changes in expression of anti-inflammatory cytokines 
(Fig. 2B,C). Since classically activated macrophages significantly rely on glycolytic metabolism, we studied lac-
tate production in THP-1 cells exposed to uremic serum. As seen in Fig. 2D, lactate production is increased in 
macrophages exposed to uremic serum. The elevated glycolysis associated with inflammatory macrophages is 
heavily dependent on hypoxia-inducible factor-1 alpha (HIF-1α) which is reproduced in our uremic model. 
NIH/3T3 cells exposed to uremia demonstrated higher HIF-1α activity consistent with the elevated lactate pro-
duction (Fig. 2E). Nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) is a key inflammatory 
transcription factor and as such, NIH/3T3 cells exposed to uremic serum demonstrate higher NFκB activation 
(Fig. 2F). We also studied macrophage markers associated with a metabolically activated  phenotype23. THP-1 
cells treated with PMA and then exposed to uremia, showed increased ABCA1, CD36, and PLIN2 expression 
Figure 2.  Monocyte/macrophage cytokine production is heightened after uremia exposure. (A) mRNA relative 
expression of cytokines in THP-1 monocytes cultured with 10% uremic versus 10% control serum. (B) mRNA 
relative expression of cytokines in HL-60 monocytes cultured with 10% uremic versus 10% control serum. (C) 
mRNA relative expression of cytokines in THP-1 macrophage cells after differentiation with PMA and treatment 
with 10% uremic versus 10% control serum. (D) Lactate levels in THP-1 cell supernatants after 24 h treatment 
with 20% control and uremic serum. Time 0 h uses supernatants of cells with serum treatment after 24 h. Time 
24–48 h uses supernatant from cells cultured in standard media with calf serum. (E) NIH/3T3 cells expressing 
HIF luciferase reporter were incubated with different concentrations of normal and uremic serum. Luciferase 
activity as reflection of HIF activation in reporter cells was measured after serum exposure for 24 h in normoxia 
(21%  O2) or hypoxia (1%  O2). * compares each serum treatment in normoxia versus hypoxia, † compares each 
oxygen concentration in uremic versus normal serum treatment. (F) NIH/3T3 cells expressing NFκB luciferase 
reporter were incubated with different concentrations of normal and uremic serum. Luciferase activity as 
reflection of NFκB activation in reporter cells was measured after serum exposure for 24 h. (G) mRNA relative 
expression analysis of metabolic macrophage markers in THP-1 monocytes treated with PMA and exposed 
to 10% uremic and normal serum. Unpaired t test, n = 3 for mRNA experiments in (A–C), n = 4 for lactate 
measurements, luciferase activity and mRNA experiment in (D–G), experiments were done in triplicate, error 
bars represent SEM *†p ≤ 0.05, **p < 0.01, ***p < 0.001. CS, normal serum; US, uremic serum.
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compared to macrophages exposed to normal serum (Fig. 2G). Similar results were found in THP-1 and HL-60 
monocytes with increased expression of PLIN2 and CD36 (data not shown). Taken together, the data dem-
onstrate that macrophage exposure to uremic serum promotes a change to an inflammatory phenotype with 
increased glycolysis and activation of HIF-1α and NFκB. Macrophages exposed to uremia also demonstrate 
increased expression of CCL2, an important macrophage-attractant chemokine as well as surface markers asso-
ciated with a metabolically activated macrophage phenotype.
Activation of HIF and NFκB in uremia is blunted by inflammatory cytokine inhibition. To 
determine the contribution of inflammatory cytokines to activation of HIF and NFκB, NIH/3T3 cells exposed to 
uremia were treated with IL6 and TNFα inhibitors. As shown in Fig. 3A, TNFα inhibition significantly decreases 
activation of NFκB in cells treated with uremic serum. No changes in NFκB activation were seen with IL-6 inhi-
bition (data not shown). Conversely, IL-6 inhibition results in a significant decrease in HIF activation in cells 
exposed to uremic serum (Fig. 3C) whereas TNFα inhibition did not have any effects on HIF activation (data 
not shown). Moreover, HIF inhibition decreased NFκB activation and NFκB inhibition decreased HIF activation 
(Fig. 3B,D). Our data demonstrate that IL6 and TNFα contribute to the activation of HIF and NFκB respectively 
in uremia. There is also a feed-forward loop between NFκB and HIF in uremia.
Adipocyte expression of cytokines is increased after exposure to uremic macrophages in 
co‑culture. In human obesity, interactions between macrophages and adipose tissue cells are known to 
enhance  inflammation24. To better delineate the cross talk between adipose tissue and macrophages in uremia 
we used a co-culture model. Human and murine macrophages were exposed to uremic sera in separate inserts 
Figure 3.  Activation of HIF and NFκB in uremia is blunted by inflammatory cytokine inhibition. NIH/3T3 
cells expressing NFκB luciferase reporter were incubated with different concentrations of normal and 
uremic serum and 5 µM of the TNFα antagonist SPD304 (A) or 10 nM of echinomycin which is a HIF-1α 
inhibitor (B). Luciferase activity as reflection of NFκB activation in reporter cells was measured after serum 
and drug exposure for 24 h. NIH/3T3 cells expressing HIF luciferase reporter were incubated with different 
concentrations of normal and uremic serum and 2 µg/ml of neutralizing anti-IL6 monoclonal antibody (C) or 
50 nM of QNZ which is an NFκB inhibitor (D). Luciferase activity as reflection of HIF activation in reporter 
cells was measured after serum exposure for 24 h in normoxia (21%  O2). Unpaired t test, n = 3. Experiments 
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and then co-cultured with adipocytes in standard media. Adipose cells and macrophages were not physically in 
contact, but the insert pores allow the transfer of soluble factors. The cytokine production profile of adipose cells 
co-cultured with uremia exposed macrophages was then examined. Adipose cells exposed to uremia-primed 
macrophages showed increased IL-6 and CCL2 expression in the human (Fig. 4A) and murine (Fig. 4B) models. 
Expression levels of IL1-α in the murine model were too low to quantify (data not shown). Furthermore, expres-
sion of IL-6, TNFα, and CCL2 was significantly higher in primary adipocytes co-cultured with uremic serum-
exposed THP-1 macrophages compared to adipocytes exposed to uremic serum alone without macrophages 
(Fig. 4C). In an alternative experiment, macrophages without uremic exposure were co-cultured with adipocytes 
previously exposed to uremic serum. In this reverse condition, macrophages did not demonstrate changes in 
cytokine expression compared to macrophages co-cultured with adipocytes that were exposed to normal serum 
(data not shown).
Increased adipose tissue macrophages (ATMS) in uremic mice present an inflammatory phe‑
notype and IL‑6 is a necessary cytokine for ATMS recruitment in uremia. To determine if the 
uremic serum-induced changes seen in the human tissue and cell models could be recapitulated in-vivo, we 
used a mouse model of uremia by adding adenine to their diet. Baseline weight of control mice was 27.7 g and 
29.7 g prior to adenine exposure in the experimental group. Mice exposed to adenine showed characteristics of 
advanced CKD including elevation of blood urea nitrogen (BUN), marked weight loss, development of anemia 
and higher platelet levels (Fig. 5A–C). Adenine induced changes in kidney histology included interstitial fibrosis, 
tubular atrophy, and 2,8-dihydroxyadenine crystals (Fig. 5D,E). Adenine exposed mice also have elevation of 
plasma inflammatory cytokines including IL-6, TNFα, resistin, and plasminogen activator inhibitor-1 (PAI-1) 
(Fig. 5F).
To investigate macrophage characteristics in our mouse model, we initially examined monocyte surface 
marker expression in peripheral blood. Adenine exposed mice had an elevated percentage of circulating mono-
cytes with higher numbers of cells bearing the surface markers CD11b (a pan-macrophage marker), CD11c 
(marker of classically activated macrophages), CD204, CD206, and CD163 (all three are markers of alternatively 
activated macrophages) (Fig. 6A). These data suggest a distinct uremic peripheral monocyte phenotype with an 
increase in both M1 and M2-like monocyte/macrophage subtypes.
We then determined the phenotype of ATMS in uremic mice by flow cytometry. Uremic mice have a higher 
percentage of  CD45+/CD64+ cells compared to control mice as shown in Fig. 6B. When stratified by surface 
markers commonly associated with classically activated macrophages, versus alternatively activated macrophages, 
subcutaneous fat (SF) depots show a preponderance of classically activated macrophages with a lower proportion 
of alternatively activated macrophages in both SF and visceral fat (VF) (Fig. 6C).
Since IL-6 is the cytokine with higher expression changes in the in-vitro adipose tissue cell and macrophage 
models, we hypothesize that IL-6 has a leading role in macrophage recruitment to adipose tissue in uremia. We 
then compared the percentage of  CD45+/CD64+ cells in uremic wild type mice compared to uremic IL-6 knock 
out (KO) mice. IL-6 KO mice were exposed to adenine supplementation in the diet and developed a similar 
phenotype to the uremic wild type counterparts (Fig. 6D). However, uremic IL-6 KO mice have reduced  CD45+/
CD64+ cells in adipose tissue compared to their uremic wild type counterparts (Fig. 6E). In contrast to wild-type 
control mice, there was no significant difference in the percentage of ATMS between uremic IL-6 KO mice and 
IL-6 KO mice with normal kidney function (Fig. 6F). The data from the in-vivo mouse models of uremia are 
Figure 4.  Adipocyte expression of inflammatory cytokines is increased after exposure to uremic macrophages 
in co-culture. (A) mRNA relative expression of cytokines in human subcutaneous adipocytes co-cultured with 
THP-1 macrophages exposed to uremic and normal human serum. (B) mRNA relative expression of cytokines 
in murine 3T3-L1 cells co-cultured with RAW 264.7 macrophages exposed to uremic and control human serum. 
(C) mRNA relative expression of cytokines in human subcutaneous adipocytes after co-culture with THP-1 
macrophages treated with normal and uremic serum compared to serum exposure alone. Unpaired t test, n = 4 
for (A) and (C), n = 3 for (B), experiments were done in triplicate, error bars represent SEM *p ≤ 0.05, **p < 0.01, 
***p < 0.001. MP, macrophages.
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consistent with prior literature describing an increase in ATMS in ESRD patients compared to controls with 
normal kidney  function14. The data is also consistent with our in-vitro uremic models as more of the ATMS 
in the uremic mice have an M1-like phenotype than an M2-like phenotype. The data also supports a possible 
mechanism of macrophage infiltration in uremia. Our data postulates that IL-6 is a key cytokine regulating 
macrophage recruitment to adipose tissue in uremia.
Uremic patients have increased adipose tissue macrophage numbers than controls indepen‑
dently of BMI. Since there is a positive correlation between ATMS infiltration and BMI in humans with nor-
mal kidney  function25, we set out to determined if there are differences in ATMS infiltration in uremic patients 
versus controls after BMI stratification.
The demographic characteristics of the ESRD and control cohorts are described in Table 1. Diabetic patients 
were intentionally excluded from the study to minimize the confounding of adipose tissue changes related to 
metabolic disorders in addition to uremia. There were more obese patients in the ESRD group than the controls 
as expected, but median weight was similar between the groups.
There was an increase in macrophage infiltration using CD163 immunostaining as a pan-macrophage marker 
in both SF and VF in ESRD participants compared to controls (data not shown) and this was maintained after 
stratifying by BMI in almost all groups (Fig. 7A,B). Data was replicated by flow cytometry of stromal vascular 
fraction (SVF) in uremic patients and controls showing higher percentage of CD45+/CD14+ cells in ESRD 
patients compared to controls (Fig. 7C,D). Specifically, SF of ESRD patients had approximately double the num-
ber of macrophages than controls and approximately 3 times more macrophages in VF than controls (Fig. 7E). 
Since our in vitro and in-vivo model demonstrated an inflammatory phenotype in macrophages exposed to 
uremia, we then hypothesized that ATMS in uremic patients have a different phenotype than macrophages in 
non-uremic conditions. Because cell size and morphology have been used to identify macrophage functional 
 phenotypes26,27, we used macrophage morphology as a surrogate of phenotype. Macrophage morphology was 
assessed by measuring macrophage non-nuclear fractions as a marker of macrophage area. Non-nuclear fractions 
were defined as areas that had positive CD163 staining but were not associated with nuclei. When macrophage 
nuclei and fractions were quantified, macrophage number and area were higher in both of the adipose tissue 
depots and in every strata of BMI (Supplemental Figures 1,2). Adipocyte size did not differ between ESRD par-
ticipants and controls in SF (data not shown). In VF, adipocytes were larger in both lean and overweight ESRD 
patients compared to controls (Supplemental Figure 3).
Figure 5.  Phenotypic characteristics of adenine diet induced chronic kidney disease mice. (A) BUN level 
(mg/dL) in WT adenine diet fed mice versus control mice. (B) Difference in % of weight change at week 2 
and week 4 of treatment between control and adenine diet treated mice. (C) Difference in hemoglobin (g/
dL), white blood cells (K/μL), and platelets (K/μL) between the control group and the adenine diet group. (D) 
Representative photographs of sections of Masson Trichrome stained renal tissue from 2 animals treated with 
control or adenine diet for 4 weeks. Left panel of control animal shows preserved tubules, whereas the right 
panel demonstrates atrophic tubules with inflammatory interstitial infiltrate, (E) Interstitial fibrosis score of 
control and adenine diet groups on Masson Trichrome stained sections. At least 10 fields per mice were used at 
20× magnification. (F) Comparison of cytokine values between the control group and the adenine diet group. 
Unpaired t test, n = 4, error bars represent SEM *p ≤ 0.05, **p < 0.01, ***p < 0.001. BUN, blood urea nitrogen. 
WT, wild type. Ade, adenine diet. WBC, white blood cells. PLT, platelets.
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Our human tissue data demonstrate an increase in macrophage recruitment to adipose tissue in uremia that 
is independent of adiposity. ESRD also drives a distinct adipose tissue macrophage phenotype with increased 
macrophage area.
Discussion
Our findings demonstrate that adipocytes and macrophages contribute to uremia-induced inflammation. Our 
data show that adipocytes and macrophages exposed to uremia increase inflammatory cytokine secretion and 
activation of NFκB/HIF1α. The uremic environment also promotes macrophage recruitment demonstrated by 
increased CCL2 expression in macrophages. We also demonstrated a positive interaction between uremia-primed 
macrophages and adipocytes. Adipocytes exposed to uremia-primed macrophages express greater inflammatory 
cytokine secretion than after exposure to uremic sera alone. In uremic mice, there is greater ATMS density than 
controls; and ATMS in uremic mice predominantly display an inflammatory phenotype. IL-6 abrogation pre-
vents recruitment of ATMS in uremic mouse models. In uremic human adipose tissue, ATMS density is greater 
compared to normal kidney function controls, independent of BMI.
In our current study, we present data supporting the concept that uremia stimulates adipocyte production 
of inflammatory cytokines and promotes lipolysis. This finding is consistent with prior studies that reported 
increased IL-6 and TNF-α expression in 3T3-L1 adipocytes exposed to uremic toxins such as indoxyl sulfate 
and p-cresyl  sulfate28,29. Furthermore, we have also demonstrated that macrophages exposed to uremia drive 
adipocytes to produce inflammatory cytokines. Uremia is a complex metabolic state seen in advanced kidney 
disease that results from accumulation of multiple toxic compounds including degradation products of protein 
metabolism, cytokines, interleukins, ions such as hydrogen, advanced glycation end products, and other metabo-
lites, as well as changes in redox state that negatively affect organ function. The contribution of each component 
of the uremic environment that drives adipose tissue metabolic changes will need to be determined in the future 
with studies of adipose tissue metabolism after exposure to increasing concentrations of uremic toxins. Interest-
ingly, despite production of inflammatory cytokines, adipocytes exposed to uremia also increase production 
of adiponectin. We previously demonstrated higher adiponectin production in adipose tissue of patients with 
advanced CKD compared to  controls1, and in this study, we observed similar results in an adipocyte cell model 
Figure 6.  Peripheral and adipose tissue macrophage characteristics in uremia. (A) Peripheral blood flow 
cytometry showing the expression of different macrophage markers in adenine diet-induced mice versus 
control. (B) Adipose tissue flow cytometry showing the % of CD45+/CD64+ cells (macrophages) in adenine 
diet mice versus control mice. (C) Difference in % of expression of CD64+/CD11c+ and CD64+/CD11c- 
macrophage phenotypes in subcutaneous and visceral fat. (D) BUN level (mg/dL) in IL6 KO mice after adenine 
diet versus IL6 KO control mice. (E) Percentage of CD45+/CD64+ cells in adenine diet treated wild type and 
IL-6 KO mice; (F) Percentage of CD45+/CD64+ cells in IL-6 KO mice treated with adenine diet versus control. 
Unpaired t test, n = 4 for (B), (D), (E), n = 6 for (A), (C), error bars represent SEM *p ≤ 0.05. SF, subcutaneous fat. 
VF, visceral fat. Ade, adenine diet. Cont, control. KO, knockout.
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exposed to uremia. Adiponectin function in uremia appears to be blunted, as demonstrated by muscle cell adi-
ponectin resistance at the post-receptor  level30 and by increased lipolysis with decreased lipogenesis in adipocytes 
exposed to  uremia31,32. Elevated adiponectin production in uremia could be a compensatory response to the 
increased inflammatory condition, worsening insulin resistance or decreased adiponectin function. Similarly 
to other groups, we have demonstrated that adipose tissue cells exposed to uremic serum demonstrate higher 
lipolysis  rates31. But in contrast to obesity, adipose tissue cells exposed to uremic serum present higher basal 
oxygen consumption rates reflecting a shift to energy production and increased basal metabolic rate (BMR). 
Higher BMR in adipose tissue may reflect a response to the enhanced energy expenditure that accompanies 
chronic inflammation and advanced kidney disease undergoing renal replacement therapy. Further studies will 
need to elucidate if the increase in OCR reflects increase in FAO or mitochondrial uncoupling and the factors 
that drive this metabolic shift.
Circulating monocytes are other important sources of inflammatory cytokines. Reports about the monocyte/
macrophage phenotype in uremia are limited. Using surface markers associated with an M1–like phenotype, 
Merino et al.33. and Bonan et al.34. described an increase in the proportion of pro-inflammatory circulating 
monocytes in uremic patients. Functional studies on cytokine expression and macrophage adhesion/migration 
properties in response to uremia are also limited to a few reports. Adesso et al.35. determined that the uremic 
toxin indoxyl sulfate enhances production of IL-6 and TNFα in macrophages also exposed to bacterial lipopoly-
saccharide. However, no description was provided on functional changes in macrophages with uremia exposure 
alone. In cell culture studies, macrophages responded to uremic serum exposure with increased migration and 
adhesion to endothelial  cells36. These early reports indicate that uremia changes macrophage phenotype. Our 
data is consistent with and adds to prior  literature37, as we demonstrate that uremic serum exposure increases 
production of inflammatory cytokines and the important macrophage chemotactic protein CCL2 in monocyte 
and macrophage human cell lines. Macrophages exposed to uremic serum have higher lactate production, reflect-
ing a switch to glycolysis, which has been described as a key feature of classically activated  macrophages38. 3T3/
NIH cells exposed to uremia had NFκB and HIF1α activation highlighting a role of both transcription factors 
in the inflammatory response of uremia. Upregulation of HIF1α and NFκB genes in uremic patients have been 
described in peripheral blood mononuclear  cells39 Our data showing activation of both transcription factors along 
with an increase in lactate release is compatible with the known existence of a positive feedback loop between 
NFκB and  HIF140,41. Furthermore, we have demonstrated that IL6 plays a key role on HIF activation and TNFα 
Table 1.  Demographic characteristics of the study participants. Age, BMI, height, weight, and albumin are 
represented as median (Q1, Q3). All categorical data is presented as number (percent). ESRD, end stage renal 
disease; BMI, body mass index; HTN, hypertension; GN, glomerulonephritis; PKD, polycystic kidney disease; 
HD, hemodialysis; PD, peritoneal dialysis. Percentage were rounded to nearest decimal point.
Demographics Controls (N = 36) ESRD (N = 41)
Age (years) median 47 (29, 53) 54 (43, 61)
BMI (kg/m2) = N; median
Normal weight (BMI < 25) N = 13 23.2 (20.57, 23.60) N = 13 22.8 (19.9, 23.9)
Overweight (BMI = 25–29.9) N = 15 26.9 (26.39, 28.8) N = 15 27.3 (26.04, 28.55)
Obese (BMI > 30) N = 8 32.66 (31.66, 33.1) N = 13 33.7 (32.9, 34.7)
Height (m) median 1.69 (1.65, 1.75) 1.72 (1.61, 1.77)
Weight (kg) median 80.27 (69.61, 87.64) 80.04 (69.84, 88.89)
Sex (female) 22 (61.1%) 20 (48.8%)
Race
Black or African American 3 (8.3%) 7 (17%)
White 32 (88.9%) 32 (78%)
Other 1 (2.8%) 2 (5%)
Ethnicity
Hispanic 2 (5.5%) 3 (7.3%)
Non-Hispanic 34 (94.5%) 38 (92.7%)
Cause of CKD
HTN NA 13 (31.7%)
GN NA 14 (34.1%)
PKD NA 3 (7.3%)
Other NA 11 (26.8%)
Previous transplant (yes) NA 6 (14.6%)
Renal replacement modality
HD NA 21 (51.2%)
PD NA 5 (12.2%)
Preemptive NA 15 (36.6%)
Albumin (g/dl) median 4.6 (4.5, 4.8) 4.5 (4.3, 4.6)
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in NFκB activation in uremia. A feed-forward loop exists between NFκB and HIF activation as NFκB drives HIF 
activation and HIF drives NFκB activation.
Moreover, uremia exposure induced expression of markers associated with a metabolically activated phe-
notype. Our findings indicate that uremia contributes to both activation and polarization of macrophages to a 
metabolic phenotype promoting inflammation as well as macrophage migration to affected organs, in our case 
adipose tissue. Taken together, these data demonstrate that macrophages play a key role in uremic inflammation. 
Further studies in all tissues in uremia are needed to determine if the inflammatory macrophage phenotype is a 
global phenomenon or is restricted to a tissue subset, which includes the adipose tissue.
Our data demonstrate a significant interaction between adipose tissue cells and macrophages in uremia as 
adipocytes express greater inflammatory cytokine production following exposure to macrophages primed by 
uremic serum. While exposure to uremic serum alone promotes an inflammatory response in adipocytes, expo-
sure to uremic macrophages promotes a much stronger adipocyte inflammatory response.
In contrast to adipose tissue in obesity, macrophages exposed to uremic adipocytes do not undergo an 
inflammatory switch. Our data highlight a significant difference between the pathogenesis of the adipose tissue 
inflammation in uremia versus obesity as it demonstrates that the macrophage inflammatory switch is primarily 
mediated by exposure to uremic serum and not to uremic adipocytes. Recently, lipid filled vesicles released by 
adipocytes have been described as a potential mechanism of ATMS  differentiation42. Further studies are needed 
to characterize the role of adipose tissue lipid release and ATMS differentiation in uremia.
The contribution of adipose tissue to the increased inflammatory state seen in kidney disease has been 
recently highlighted by Sodhi et al.43. Using a partial nephrectomy model in mice, the study demonstrates 
increased production of systemic inflammatory cytokines by adipocytes that worsens with high fat diet. The 
authors also propose that alterations of the redox state in adipocytes play a role in the pathogenesis of uremic 
adipocyte dysfunction. Our study is consistent with the published data as our mice model of kidney disease after 
adenine supplementation showed increased peripheral inflammatory cytokines. On the other hand, we focused 
on ATMS content as a potential pathway for adipocyte dysregulation. The macrophage content in adipose tissue 
of non-obese humans can vary between 1 and 30%. In obesity, the content of ATMS can double, contributing 
to low-grade chronic inflammation and adipose tissue  dysregulation16. In this study, we used a mouse model 
to study ATMS in uremia. Our uremic mice demonstrated higher peripheral monocyte numbers compared to 
control mice and consistent with human peripheral monocyte studies with a greater percentage of  CD14+/CD16+ 
monocytes in dialysis patients compared to healthy  controls33,34. In contrast to the human findings, peripheral 
Figure 7.  Adipose tissue macrophage counts in uremic patients versus controls stratified by BMI. (A) Mean 
number of CD163+ cells per 100 adipocytes in subcutaneous adipose tissue. (B) Mean number of CD163+ cells 
per 100 adipocytes in visceral adipose tissue. (C) CD45+/CD14+ % cells (macrophages) in subcutaneous 
adipose tissue of kidney donors compared to kidney transplant recipients (n = 4 per group). (D) CD45+/
CD14+ % cells in visceral adipose tissue (of kidney donors compared to kidney transplant recipients. Lines 
link participant pairs (donor and recipients) that were analyzed on the same day (E) Macrophage fold change 
between donors and recipients in subcutaneous versus visceral fat. Mann–Whitney U test, error bars represent 
IQR. *p ≤ 0.05. SF, subcutaneous fat. VF, visceral fat. ESRD, end stage renal disease.
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monocytes in uremic mice express a greater variety of cell surface markers including markers associated with 
classically and alternatively activated macrophages, which may be due to lack of discrimination of M1 and M2 
markers for metabolically activated  macrophages23. In human obesity, recruitment of peripheral monocytes 
and local proliferation of resident macrophages contribute to the increased numbers of  ATMS44,45. The source 
of increased ATMS in uremia needs to be determined but higher numbers of circulating peripheral monocytes 
in uremia as well as elevated CCL2 and IL-6 in the cell models suggest a preferential role of monocyte recruit-
ment to adipose tissue.
Uremic mice demonstrate higher ATMS density compared to control mice and macrophages in uremic 
adipose tissue show predominantly a classically activated phenotype. The macrophage phenotype in our mouse 
model is consistent with the inflammatory phenotype found in our cell culture experiments and is consistent 
with the phenotype described in the obesity  literature18, reinforcing the potential contribution of adipose tissue 
to the uremic inflammatory condition.
In uremic patients, among a variety of inflammatory biomarkers, IL-6 has been demonstrated to be a robust 
predictor of cardiovascular disease and all-cause  mortality46. Besides its role as a biomarker in CKD, IL-6 signal-
ing leads to recruitment of monocytes to sites of  inflammation47. Our uremic mouse model demonstrates that 
IL-6 plays a key role in macrophage recruitment to adipose tissue. IL-6 KO uremic mice had lower ATMS density 
when compared to wild type uremic mice. There were also no differences in ATMS density in uremic IL-6 KO 
mice compared to non-uremic IL-6 KO mice highlighting the necessary role of IL-6 in macrophage infiltration 
in uremia. Because ATMS can contribute up to 50% of the production of circulating IL-625 it is possible that a 
decrease in adipose tissue macrophage infiltration in uremic mice could potentially result in a decrease in the 
overall inflammatory state of uremia.
Our study provides additional findings on adipose tissue as a source of inflammation in uremic patients. We 
demonstrated greater macrophage density in different BMI strata in visceral and subcutaneous adipose tissue 
depots in ESRD patients compared to controls, indicating that macrophage infiltration in uremia is unrelated 
to the degree of adiposity. Our data are consistent with findings by Gertow et al.48 who found more  CD68+ 
cells in subcutaneous adipose tissue of non-obese uremic patients compared to healthy controls. The authors 
also described smaller adipocytes in patients with CKD. On the other hand, our ESRD patients did not have 
significant differences in adipocyte size in subcutaneous adipose tissue while adipocytes were larger in visceral 
adipose tissue of non-obese uremic patients. The discrepancy could be explained by our strict BMI matching 
between groups and by the separation of the lean and overweight sub-groups. Visceral fat is considered the more 
functional adipose depot and larger adipocytes in uremic patients could be a reflection of altered adipocyte 
metabolism associated with uremia.
Our study has some limitations. Macrophage characterization in our tissue experiments was based on stand-
ard surface markers generally associated with classically activated versus alternatively activated macrophage 
phenotypes. Recently, there has been additional characterization of macrophages in metabolic diseases such as 
obesity and other  disorders23. Functional as well as phenotypic characterization of tissue macrophages should be 
considered in vivo uremic models as it is possible that uremia-primed macrophages have a unique phenotype. 
We utilized an adenine nephropathy mouse as a model of advanced kidney disease. Further studies to explore 
the role of our findings will require replication in different mouse models of uremia. Although our study focused 
on the role of IL-6 in ATMS recruitment, other inflammatory cytokines and uremic toxins may also play a role 
in macrophage recruitment and will need to be investigated.
Uremic patients have clinical evidence of chronic inflammation and severe uremic inflammation is predic-
tive of adverse outcomes. Uremia promotes changes in both adipose tissue and macrophages in a cooperative 
fashion that enhance the inflammatory condition. Although the specific contribution of adipose tissue to uremic 
inflammation remains unclear, our co-culture studies demonstrate an interaction between adipocytes and mac-
rophages that drives additional adipocyte inflammation. Findings in both our uremic mouse model and human 
tissue are consistent with the overall concept that interplay between uremia activated macrophages and adipose 
tissue augments the inflammatory process in uremia. The role of uremia-primed macrophages driving tissue 
dysfunction in non-adipose tissues will need to be determined in the future.
Methods
Cell culture. 3T3-L1 cells were used as a model of murine adipocytes. THP-1 monocyte-like cells and HL-60 
promyeloblasts were used as human monocyte cell lines and were maintained in suspension. THP-1 cells can 
be differentiated to adherent macrophages by using Phorbol-12-mystrated-13-acetate or PMA. RAW 264.7 cells 
were used as a murine macrophage cell line. All cell lines were purchased from ATCC and cultured according 
to the manufacturer’s recommendations. Briefly, 3T3-L1 cells were cultured in 10% bovine calf serum (ATCC 
30-2030) supplemented DMEM. When confluent, cells underwent a pre-adipose to adipose like conversion by 
replacing medium to DMEM containing 10% fetal bovine sum (FBS), 1 µM dexamethasone (D4902; Sigma), 
0.5 mM 3-isobutyl-1-methylxanthine (I5879; Sigma), and 1 µg/mL insulin (I0516; Sigma). 3T3-L1 adipocyte 
like cells were maintained in DMEM 10% FBS and 1 µg/mL insulin. The RAW 264.7 cells were maintained in 
10% bovine calf serum supplemented DMEM. THP-1 human monocytic cells were maintained in RPMI-1640 
Medium (ATCC 30-2001) supplemented with 10% FBS and 2-mercaptoethanol (21985023; Gibco) to a final 
concentration of 0.05 mM. Suspension THP-1 cells (500,000 cells per well) were differentiated into adherent 
plates using 75 ng/mL of PMA (P8139; Sigma) for 72 h. HL-60 human promyeloblast cells were maintained in 
Iscove’s Modified Dulbecco’s Medium (ATCC 30-2005) supplemented with 20% FBS.
Human pre-adipocytes (HPAd) were purchased from Sigma (802S-05A). Cells were grown and differentiated 
to human adipocytes (HAd) following manufacturer’s instructions. Briefly, 44,000 preadipocytes per  cm2 were 
seeded and incubated until they reached 100% confluence. Confluent cells were cultured with Human Adipocyte 
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Differentiation Medium (811D-250) for 15 days until cells had lipid droplets. One day prior to the assay, cells 
were starved in Human Adipocyte Starvation Medium (811S-250). Experiments with cell lines were performed 
within 6 months of purchase and cells had tested negative for mycoplasma before their use.
Adipocyte—macrophage co‑culture. 3T3-L1 with RAW 264.7 and HAd with THP-1 were cocultured 
using a transwell system. Adipocytes were differentiated at the bottom of a 12-well plate and maintained in dif-
ferentiation media with calf serum. Separately from the adipocytes, macrophages were seeded in 0.4 µm pore-
size membrane inserts (353180; Corning) and treated with 10% normal or uremic human serum for 24 h. After 
serum treatment, media was washed, and inserts containing pretreated macrophages were placed over the adi-
pocytes and cocultured in standard differentiation media for 24 h. The co-culture experiments were repeated 
with macrophages at the bottom of the 12-well plate and adipocytes exposed to uremia in the membrane inserts.
Human serum treatment. For the experiments with uremic serum exposure, uremic serum was collected, 
prior to hemodialysis (HD) after the longest break (after 2 dialysis free days), from a pool of stable in-center 
hemodialysis patients. 10 mL of uremic serum were drawn from approximately 100 HD patients in their usual 
state of health (we excluded patients with Hepatitis C, Hepatitis B or acute infection). For the normal serum, 
10 mL of normal serum were drawn from 50 kidney donors in their usual state of health before donation. Serum 
from dialysis patients and kidney donors was pooled, filtered, and aliquoted in small vials to be frozen at − 80 °C 
for cell experiments.
Quantitative real time‑PCR. Total RNA from the cell experiments was extracted using TRIzol rea-
gent (15596026; Invitrogen). cDNA was obtained using the High-Capacity cDNA Reverse Transcription Kit 
(4368814; Applied Biosystems). Quantitative Polymerase Chain Reaction (qPCR) was performed in triplicates 
and performed using QuantStudio 12 K Flex Real-Time PCR System (Thermo Fisher Scientific). TaqMan Gene 
expression assays used for the experiments are detailed in Supplemental Table 1. Expression levels were cal-
culated using the relative comparative CT  (2−∆∆Ct) method after normalization to GAPDH as an endogenous 
control.
Glycerol release assay. Differentiated 3T3-L1 cells were exposed to control or uremic serum in 12-well 
plates. After 24 h, cells were washed, and media replaced by fresh DMEM 10% FBS. The cell culture supernatants 
were collected after 24 h and 40 h. Released free glycerol was measured using the Glycerol Assay Kit (MAK117, 
Sigma-Aldrich) according to the manufacturer’s instructions. Results were normalized to protein concentration 
(µg/µL).
Oxygen consumption rates (OCR) measurement. 3T3-L1 cells were plated and differentiated on Sea-
horse XF 24-well plates (100777-004, Agilent). Cells were exposed to control or uremic serum for 24 h, and 
incubated in Seahorse XF DMEM medium (103334-100, Agilent) supplemented with 5 mM glucose (103577-
100, Agilent) at 37  °C for 45 min without  CO2 just before running the experiments. Seahorse XF Cell Mito 
Stress Test Kit (103015-100, Agilent) was used with the final respiratory modulators concentration of 1.5 µM for 
Oligomycin, 1 µM for FCCP, and 0.5 µM for Rotenone/Antimycin A. OCR measurements were obtained using 
the Seahorse XFe24 Analyzer, and normalized to protein concentration (µg/µL).
Extracellular lactate measurement. THP-1 adherent cells were exposed to serum in 12-well plates. 
After 24 h, cells were washed, and media replaced by fresh RPMI 10% FBS. The cell culture supernatants were 
collected after 24 h and 48 h. Extracellular l-lactate concentration was measured using the EnzyChrom l-lactate 
Assay Kit (ECLC-100, BioAssay Systems) according to the manufacturer’s protocol. Results were normalized to 
total protein content (µg).
Patients. Participants were recruited from the Thomas Jefferson University Hospital (TJUH) transplant 
program. The study protocol was approved by the Institutional Review Board at TJUH and informed consent 
was obtained from each participant. All methods were carried out in accordance with relevant guidelines and 
regulations (Declaration of Helsinki). Patients with diabetes pre-kidney transplantation were excluded. The con-
trol group consisted of kidney donors. While under general anesthesia for kidney donation or transplantation, 
250 mg of omental visceral fat and subcutaneous fat were obtained. Recruitment of patients and procedures have 
been previously described by  us14.
Histology. Adipose and kidney tissues were paraffin embedded. Kidney sections of control and adenine 
diet mice were stained with Masson Trichrome in our pathology core. An interstitial fibrosis (IF) score was 
obtain using previously described  criteria49–51 on at least 10 randomly selected areas at 20× magnification in 
in each mice. Scores were verified by 2 different investigators blinded to the study groups. Inter-observer vari-
ability was < 10%. In brief, IF of 1 represents an area with interstitial fibrosis of less than 25%, 2 represents 
IF of an area between 26 and 50%, 3 represents IF of an area between 51 and 75% and 4 represents IF of an 
area > 75%. Paraffin-embedded sections adipose tissue were immunostained as previously described by us with 
minor  modifications14. Briefly, sections were deparaffinized, rehydrated and antigen retrieval was performed in 
10 mM sodium citrate, pH 6.0 with 0.05% Tween-20 for 10 min using a pressure cooker. Sections were blocked 
with 3% hydrogen peroxide for 15 min followed by incubation using an avidin–biotin blocking kit (AB972, 
BioCare Medical) to block endogenous biotin. After incubation with 10% goat serum for 1 h, sections were 
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incubated with primary antibody overnight at 4 °C (CD163 (MRQ-26), Sigma). Antibody binding was detected 
using a biotinylated secondary antibody (BA-9200, Vector) and the Vectastain ABC HRP Kit (PK-4000, Vector). 
Immunoreactivity was revealed using 3,3′ diaminobenzidine with a liquid DAB kit (K346811-2, Agilent Tech-
nologies). ATMS infiltration was measured as the number of  CD163+ cells with nuclei in 10 randomly chosen 
fields per adipose tissue depot and participant at 40× magnification and evaluated by two independent blinded 
investigators. Non-nuclear contiguous  CD163+ areas, referred to as non-nuclear fractions, were also counted. To 
evaluate the relative contribution of the non-nuclear fractions, we divided the number of fractions per image by 
3, which best represented their smaller size, as compared to  CD163+ staining with nuclei. The average adipocyte 
area was calculated for each image by dividing the image area, which was 95,000 square microns for all images, 
by the number of adipocytes in each image.
Animal care and use. 8 to 10 weeks old male C57BL/6 mice (Strain 000664) and B6.129S2-Il6tm1Kopf/J 
(Strain 002650) were obtained from Jackson Laboratories and fed a standard diet (PicoLab Rodent Diet 20, 5053) 
or 0.2% adenine-containing diet (Modified LabDiet PicoLab Rodent Diet 20, 5053, with 0.2% adenine A8626; 
Sigma) ad libitum for 4 to 6 weeks. After development of kidney disease, mice were euthanized by  CO2 asphyxi-
ation. After euthanasia, blood was obtained by intracardiac puncture and dorso-lumbar and epididymal fat pads 
were isolated. All animal procedures were in compliance with protocols approved by the Institutional Animal 
Care and Use Committee at Thomas Jefferson University. All the methods were carried out in accordance with 
relevant guidelines and regulations. The study was carried out in compliance with the ARRIVE guidelines.
Blood immunophenotyping by flow cytometry (FCM). Performed from retro-orbital blood. Briefly, 
from 10 µL of whole blood, red cells were lysed with ACK Lysing Buffer (A1049201; Gibco). Samples were 
washed with 1% BSA in PBS and incubated in Fc-block (antiCD16/32; 101302; BioLegend) on ice. Cell surface 
markers were stained at 4 °C with antibodies described in Supplemental Table 2. After cell fixation, 50 µL count-
ing beads (C36950; Molecular Probes) were added for accurate cell counting. Cells were sorted on a BD LSR 
Fortessa cell analyzer and data analyzed using FlowJo v10.6 software.
Adipose tissue macrophage flow analysis. Dorso-lumbar and epididymal fat pads of normal and ure-
mic male mice (n = 4 per experiment) were used for characterization of ATMS. For human ATMS studies, 4 
recipients of kidney transplant and 4 healthy kidney donors were included. Stromal vascular fractions were iso-
lated and separated from adipocytes as described  previously52. The SVF pellet was resuspended in 0.5 mL RBC 
Lysis Buffer (eBioscience) and then placed in FACS buffer (PBS with 1% heat inactivated FBS, 1 mM EDTA, and 
25 mM HEPES). Cells were incubated in Fc-block (antiCD16/32) on ice and stained with indicated antibodies. 
For viability assessment, cells were suspended in FACS buffer containing DAPI (0.2  µg/mL). Antibodies for 
flow cytometry are provided in Supplemental Table 2. Cells were sorted on an LSR II Flow Cytometer (BD Bio-
sciences) and data were analyzed using FlowJo 10.6 software.
Western Blot. Protein extraction, quantification, and immunoblotting were performed as previously 
 described1. Primary antibodies used include anti-alpha 1 Sodium Potassium ATPase (ab7671; Abcam), anti-
adiponectin (2789; Cell Signaling Technology), and anti-β-actin (A5441; Sigma).
Blood urea nitrogen (BUN). Analyzed from murine retro-orbital blood with the QuantiChrom Urea 
Assay Kit (DIUR-100) as directed by the manufacturer.
Complete blood count (CBC). Analyzed in 50 µL of murine whole blood in a GENESISTM Veterinary 
Hematology System by the Translational Research/Pathology Core at the Sidney Kimmel Cancer Center.
Cytokine analysis. Plasma IL-6, TNFα, insulin, resistin, and PAI-1 levels were measured using a Milliplex 
MAP Mouse Adipokine Magnetic Bead Panel (MADKMAG-71K; EMD Millipore) and analyzed by Luminex 
xMAP in a FLEXMAP 3D System.
Luciferase activity. NIH/3T3 cells expressing NFκB luciferase reporter and HIF Luciferase reporter 
(RC0015 and LR0128, Panomics, CA) were seeded in 12-well plates with 1 × 105 of cells per well. The next day, 
the media was changed to 5/10/20% normal serum or uremic serum in DMEM and cells were incubated for 
24 h. 5 µM of SPD304 (S1697; Sigma) which is a TNFα antagonist; 2 µg/mL of neutralizing anti-IL6 monoclonal 
antibody (MAB406; R&D Systems), 10 nM of echinomycin (SML0477; Sigma), which is a HIF-1α inhibitor and 
50 nM of QNZ (S4902; Selleckchem), which is an NFkB inhibitor, were added to cells cultured in control and 
uremic serum for 24 h. Luciferase activity was measured according to the manufacturer’s protocols. HIF lucif-
erase activity was measure in normoxia (21%  O2) and hypoxia (1%  O2) using a hypoxia chamber.
Statistical analysis. All results were expressed as mean and standard error of the mean for normalized 
data or median and interquartile range for non-normalized data. Data were analyzed using two-tailed t tests 
for comparisons between two groups for normalized data and Mann–Whitney U test for non-normal data. A p 
value of ≤ 0.05 was considered statistically significant.
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